Carlisle Companies Incorporated (CSL)

Return on equity (ROE)

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income US$ in thousands 767,400 924,000 421,700 320,100 472,800
Total stockholders’ equity US$ in thousands 2,829,000 3,024,400 2,629,500 2,537,700 2,642,800
ROE 27.13% 30.55% 16.04% 12.61% 17.89%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $767,400K ÷ $2,829,000K
= 27.13%

To analyze Carlisle Companies Inc.'s return on equity (ROE) over the past five years, we can observe a fluctuating trend that reflects the company's efficiency in generating profits from shareholders' equity.

In 2023, the ROE decreased to 27.13% from 30.55% in 2022. Although the ROE declined, it remained relatively high compared to previous years. This indicates that Carlisle Companies Inc. was still able to generate a significant return for its shareholders in 2023.

The highest ROE was recorded in 2022 at 30.55%, demonstrating a strong performance in utilizing equity to generate profits. This improvement from 2019 to 2022 suggests that the company was effectively managing its assets and liabilities to maximize returns to shareholders.

In 2021, the ROE was at 16.04%, indicating a decrease from the previous year. This decrease may suggest challenges in maintaining profitability or inefficient use of equity in that particular year.

Similarly, in 2020, the ROE was 12.57%, the lowest among the years analyzed. This could indicate potential issues affecting the company's ability to generate returns on equity efficiently, such as operational inefficiencies or macroeconomic factors.

Overall, the fluctuation in ROE for Carlisle Companies Inc. over the period indicates variations in the company's ability to generate profits from shareholders' equity. The company's management may need to focus on sustaining or improving ROE levels to ensure continued profitability and shareholder value in the future.


Peer comparison

Dec 31, 2023

Company name
Symbol
ROE
Carlisle Companies Incorporated
CSL
27.13%
West Pharmaceutical Services Inc
WST
20.60%